Subthreshold Micropulse Photocoagulation for Persistent Macular Edema Secondary to Branch Retinal Vein Occlusion including Best-Corrected Visual Acuity Greater Than 20/40.
Subthreshold Micropulse Photocoagulation for Persistent Macular Edema Secondary to Branch Retinal Vein Occlusion including Best-Corrected Visual Acuity Greater Than 20/40.
复制标题
DOI：
10.1155/2014/251257
复制
发表时间：
2014
影响因子：
1.9
通讯作者：
Murakami A
中科院分区：
文献类型：
--
作者：
Inagaki K;Ohkoshi K;Ohde S;Deshpande GA;Ebihara N;Murakami A
为评价阈值下微脉冲半导体激光光凝（subthreshold micropulse diode laser photocoagulation，SMDLP）治疗视网膜分支静脉阻塞（branch retinal vein occlusion，BRVO）继发黄斑水肿的疗效，包括最佳矫正视力（best corrective visual acuity，BCVA）> 20/40。发病后，所有患者在治疗前至少随访6个月。使用基线Snellen视力将眼睛分类为BCVA ≤ 20/40（组I）或BCVA > 20/40（组II）。主要结果指标为6个月时光学相干断层扫描（OCT）和最佳矫正视力（BCVA）的中心黄斑厚度（CMT）减少。在6个月时的总受试者库中，BCVA没有显着变化，但CMT显着降低。第I组在3个月时CMT无显著变化，但在6个月和12个月时显著降低。第II组在3个月时CMT略微显著降低，在6个月时显著降低。在继发于BRVO的持续性黄斑水肿患者中，SMDLP似乎可以控制黄斑水肿，视网膜损伤最小。我们的研究结果表明，SMDLP是治疗BCVA > 20/40的BRVO患者黄斑水肿的有效方法。
To assess the efficacy of subthreshold micropulse diode laser photocoagulation (SMDLP) for persistent macular edema secondary to branch retinal vein occlusion (BRVO), including best-corrected visual acuity (BCVA) > 20/40, thirty-two patients (32 eyes) with macular edema secondary to BRVO were treated by SMDLP. After disease onset, all patients had been followed for at least 6 months prior to treatment. Baseline Snellen visual acuity was used to categorize the eyes as BCVA ≤ 20/40 (Group I) or BCVA > 20/40 (Group II). Main outcome measures were reduction in central macular thickness (CMT) in optical coherence tomography (OCT) and BCVA at 6 months. In the total subject-pool at 6 months, BCVA had not changed significantly but CMT was significantly reduced. Group I exhibited no significant change in CMT at 3 months but exhibited significant reductions at 6 and 12 months. Group II exhibited a marginally significant reduction in CMT at 3 months and a significant reduction at 6 months. In patients with persistent macular edema secondary to BRVO, SMDLP appears to control macular edema with minimal retinal damage. Our findings suggest that SMDLP is an effective treatment method for macular edema in BRVO patients with BCVA > 20/40.
登录
查看更多内容
影响因子：
8.2
作者：
Hudson, C;Flanagan, JG;McLeod, D
通讯作者：
McLeod, D
影响因子：
4.1
作者：
Parodi, M. B.;Iacono, P.;Ravalico, G.
通讯作者：
Ravalico, G.
影响因子：
4.1
作者：
Hudson, C;Flanagan, JG;McLeod, D
通讯作者：
McLeod, D
影响因子：
8.1
作者：
Hayreh, Sohan Singh;Zimmerman, M. Bridget
通讯作者：
Zimmerman, M. Bridget
影响因子：
13.7
作者：
Brown, David M.;Campochiaro, Peter A.;Murahashi, Wendy Yee
通讯作者：
Murahashi, Wendy Yee